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Abstract
Evaluating patients with acute chest pain presenting to the
emergency department remains an ongoing challenge. The
spectrum of etiologies in acute chest pain ranges from minor
disease entities to life-threatening diseases, such as pulmo-
nary embolism, acute aortic dissection or acute myocardial
infarction (MI). The diagnosis of acute MI is usually made
integrating the triad of patient history and clinical presenta-
tion, readings of 12-lead ECG and measurement of cardiac
troponins (cTn). Introduction of high-sensitivity cTn assays
substantially increases sensitivity to identify patients with
acute MI even at the time of presentation to the emergency
department at the cost of specificity. However, the proportion
of patients presenting with cTn positive, non-vascular cardiac
chest pain triples with the implementation of new sensitive
cTn assays increasing the difficulty for the emergency phy-
sician to identify those patients who are at need for invasive
diagnostics. The main objectives of this mini-review are 1)
to discuss elements of disposition decision made by the
emergency physician for the evaluation of chest pain
patients, 2) to summarize recent advances in assay technol-
ogy and relate these findings into the clinical context, and
3) to discuss possible consequences for the clinical work and
suggest an algorithm for the clinical evaluation of chest pain
patients in the emergency department.
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Introduction
Evaluating patients with acute chest pain in the emergency
department (ED) remains difficult despite an exponential
growth of published research including innovations in diag-
nostic methods: Patients with acute coronary syndrome
(ACS) including acute myocardial infarction (MI) should be
effectively identified by the emergency physician in a timely
manner to initiate specific clinical actions. Patients who do
not have ACS or alternative high-risk situations should be
safely discharged (1).
Triage decision in the ED is usually straightforward in
patients presenting with typical cardiac chest pain and
ST-segment elevation in the 12-lead ECG wFigure 1; (2)x. In
contrast, disposition decision in patients with non-ST-eleva-
tion acute coronary syndrome wNSTE-ACS; (3, 4)x is an
ongoing challenge (5, 6): The disposition decisions of the
ED physician for patients with NSTE-ACS cannot be made
by the use of time-dependent changes of cTn levels alone
but are done by the integration of the triad of a) clinical
presentation, b) readings of 12-lead ECG, and c) measure-
ment of cardiac biomarkers, such as cTn, and/or MB-isoen-
zymes of creatine kinase and myoglobin at admission, and
6–12 h later wFigure 1; (4, 7)x. The evaluation should include
formal risk stratification using risk assessment tools, such as
the TIMI, PURSUIT or GRACE risk scores (8, 9), because
subjective risk assessment by emergency physicians appears
cloudy due to the fact that important risk predictors, such as
age and known coronary artery disease are often not ade-
quately addressed (10). In particular situations, an earlier
decision can be made by measuring cTn and ECG even 2 or
3 h after presentation to the ED to accelerate disposition
decision (11, 12). Specific diagnostic work-up including
computer tomography (CT) may be necessary for other dif-
ferentials, such as suspected pulmonary embolism or aortic
dissection. Using those various items for risk assessment, the
ED physician has to decide whether the affected patient
should be admitted to 1) an intervention (e.g., operating the-
atre, catheterization laboratory, or pharmacological interven-
tions using thrombolysis), 2) the intensive care unit, 3) the
coronary care unit, 4) a telemetry ward, 5) a hospital ward
or 6) can be safely discharged into ambulatory care after
non-invasive cardiac stress testing in the majority of cases.
Up to now, the practical consequences of the introduction
of new, high-sensitivity assay technologies to measure cTn
have not been adequately addressed for the work in the ED:
cTn levels above the cut-off-limit alone with a rise or fall of
concentration does not equal a diagnosis of MI. Non-vascular
cardiac chest pain, such as acute heart failure due to hyper-
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Figure 1 Suggested algorithm for decision-making in patients presenting with acute chest pain to the emergency department.
Triage decision is made using the triad of clinical signs and symptoms, results of 12-lead electrocardiogram and results of troponin testing.
While ST-elevation myocardial infarction is straightforward, non-ST elevation acute coronary syndrome is challenging and affected patients
need observation including follow-up 12-lead ECG and biomarker testing. Modified from (4).
Table 1 Definition of acute myocardial infarction as practically used in patients presenting with acute chest pain to the emergency
department. Adapted from (13).
Detection of a rise and/or fall of cardiac biomarkers (preferably cTn) with at least one value above the 99th percentile of the upper
reference limit of a healthy reference population and with at least one of the following:
Typical symptoms of cardiac ischemia
ECG changes indicative of new ischemia (new ST-T changes or new left bundle branch block)
Development of pathological Q-waves in the ECG
Imaging evidence of new loss of viable myocardium or a
Sudden, unexpected cardiac death, involving cardiac arrest, often with symptoms suggestive of myocardial ischemia, and accompanied
by presumably new ST elevation or new left bundle branch block, and/or evidence of fresh thrombus by coronary angiography
and/or autopsy
tension may also be associated with rise and fall of cTn
levels (13, 14). cTn is an extremely specific marker of car-
diac injury (15, 16), however, acute myocardial damage is
not specific to either MI or ACS.
The main objectives of this minireview are 1) to discuss
elements of disposition decision made by the emergency
physician for the evaluation of chest pain patients, 2) to sum-
marize recent advances in assay technology and relate these
findings into the clinical context, and 3) to discuss possible
consequences for the clinical work and suggest an algorithm
for the clinical evaluation of chest pain patients in the ED.
Cardiac troponins: past
The clinical definition of myocardial infarction includes a
rise and/or fall of cardiac biomarkers (preferably cTn) with
at least one value above the 99th percentile of the upper
reference limit of a healthy reference population wTable 1;
(15, 17)x. Troponin I and T are structural proteins of the
cardiomyocyte, and circulating levels of cTnI and cTnT can
be measured using isoform-specific antibodies (16, 18).
Increases of circulating cTnI or cTnT concentrations indicate
cardiac muscle cell necrosis and are clinically used for the
diagnosis of acute MI (17, 19). After the loss of integrity of
cardiac cellular membranes, cardiac biomarkers diffuse into
the cardiac interstitium, lymphatics, and microvasculature
and can be measured in the peripheral circulation (20). The
predominant portion of cTn (approx. 95%) is bound via tro-
pomyosin to actin filaments of the sarcomere, while a small
proportion of cTnI (6%–8%) and cTnT (3%–8%) is probably
located in the soluble cytoplasmic pool of the cardiac myo-
cytes (19, 21). Considering methodological aspects of those
experimental studies and the poor solubility of cTn in cyto-
plasm, it is probably better to use the term ‘‘early appearing
pool’’ but not ‘‘cytoplasmic pool’’ (16).
Cardiac troponins are currently considered the most sen-
sitive and specific biomarkers of myocardial damage (4,
15–17, 22, 23). Increased levels of cTn levels can be meas-
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ured during occlusion of large epicardial coronary arteries,
increased myocardial strain, sepsis, exposure to toxins,
inflammation or trauma (13). Dynamic changes of cTn
release after myocardial damage depends on the intracellular
compartmentalization of cTn: Irreversible damage of a car-
diac myocytes induces immediate release of the ‘‘early
appearing pool’’ of cTn followed by a more continuous
release of the myofibril-bound troponins (20). cTn levels
usually peak at 12–24 h after onset of chest pain and may
remain abnormal up to 2 weeks in large MI (20, 24). Small
increases of cTn, which may be due to plaque rupture result-
ing in microinfarction or non-coronary reasons of myocyte
necrosis, such as in acute heart failure, sepsis or tachycardia,
may be related to the release of cTn from the early appearing
pool of cTn due to cell membrane instability induced by
ischemia, wall strain or toxins (13).
During the introduction of cTn assays in routine practice
in the late 1990s, evaluation of patients with acute MI
revealed that cTn assays are more sensitive for small areas
of MI than those for CK-MB assays resulting in confusing
situations due to the used definition of MI at that time (25).
The precision of those former cTn assays was low. Since
cTn assays have been validated by the use of the former
WHO definition of acute MI using CK-MB assays as gold
standard (25), increased cTn levels have been seen in ACS
patients with CK-MB levels within the normal reference lim-
its. Also of interest, increased levels of circulating cTn with-
out accompanying increases of CK-MB are associated with
increased risk of death, and acute MI. Even small increases
of cTn levels support to identify ACS patients at increased
risk, who benefit from early invasive therapy (1, 4).
The high specificity of increased cTn levels for myocardial
damage measured by current assay technology have been
acknowledged by recent guidelines (3, 4, 26) and routine
evaluation of chest pain patients using biologic markers, such
as CK-MB or myoglobin have been questioned (15). Meas-
urement of CK-MB may have some value in the interpreta-
tion of reinfarction in patients with already increased cTn
levels due to recent MI or in patients with increased cTn
levels due to renal dysfunction. Before changing the practice
of initial assessment of chest pain patient in the ED, it is
prudent to check the used laboratory methods of cTn meas-
urement. Different approaches than those suggested above
may be applied with the use of point-of-care cTn measure-
ments, which often display a lower sensitivity than modern
high-sensitivity cTn assays used in clinical laboratory (27).
Cardiac troponins: present
During recent years, cTn assay technology has been consid-
erably improved including improvements of analytical sen-
sitivity and precision (23, 28). cTn assays, which are able to
measure circulating cTn levels in more than 50% of a normal
reference population, have been suggested to be called
‘‘high-sensitive’’ cTn assays (29). In the meantime, cTn lev-
els can even be measured in )80% of healthy people with
a coefficient of variation -10% at the recommended cut-
point (18, 30). High-sensitivity assays are 1000–10,000-fold
more sensitive than the original first generation assays due
to improvement of epitope selection of antibodies and inno-
vative capture and detection techniques (1).
The analytical sensitivity and high precision of sensitive
cTn assay technology enables to lower the cTn cut-off-point
for diagnosis of acute MI with accordance to the current
definitions (cutpoint defined as the 99th percentile of the
upper reference limit of a healthy reference population (16,
17); Figure 2). The use of a population-defined upper limit
of normality at the 99th percentile results in a 160% increase
of chest pain patients diagnosed with acute MI and a 200%
increase of cTn positive patients with non-coronary cardiac
chest pain (14). Additionally, more patients with acute MI
display increased hs-cTn levels even at the time of presen-
tation at the ED (11, 14, 31–33).
Due to the sensitivity and specificity of cardiac troponins
for detecting myocardial damage, measurement of cTn is the
ideal biomarker to diagnose acute MI, perform risk stratifi-
cation in affected patients and initiate specific clinical action
(34). Subsequently, cTnI or cTnT are the biologic markers
of choice in the evaluation of patients with chest pain (15,
16). However, the introduction of these new, high-sensitivity
assays to measure cTnT or cTnI may have several implica-
tions for clinical practice.
1. The definition of the cutpoint at the 99th percentile of a
healthy reference population is derived from an epide-
miological standpoint. The clinical impact of this defi-
nition is currently not well characterized although studies
indicate that even small elevations of cTn levels indicate
worse prognosis (35–37). In addition, there is currently
no standardization of a reference population, which leads
to variations of the 99th percentile by demographics and
according to the screening methods used to exclude sig-
nificant cardiac disease: More intense screening of car-
diovascular disease reduced the 99th percentile of cTnI
from 44 ng/L to 28 ng/L in the Perspective Study of the
Vasculature in Uppsala Seniors (38). Additionally, there
is no consensus on the use of age-specific reference inter-
vals and gender dependent cutpoints for cTn.
2. Using high-sensitivity assays, low amounts of cTn
released from cardiomyocytes during strenuous exercise
or tachycardia can be measured in apparently healthy
people even in the absence of irreversible myocardial
damage (13). This may occur during benign tachyarrhyth-
mic events, such as in atrial tachyarrhythmia, in AV-node
reentrant tachycardia exemplary or during strenuous exer-
cise as summarized by Michielsen et al. (39). It is cur-
rently not clarified whether irreversible damage of
myocardial cells or a transient leakage of cTn from the
early appearing pool is responsible for this observation
(13, 18). Delayed-enhancement cardiac magnetic reso-
nance imaging in a marathon study supports the release
from the ‘‘early appearing pool’’ without irreversible
damage of myocytes. Increased membrane permeability
has been suggested to be a likelier mechanism than myo-
cardial necrosis for exercise-induced cTn release (13, 40).
These highly sensitive cTn assays may lead to an
increased proportion of patients with cTn levels above
the cutpoint and may increase the admission rate of
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Figure 2 Schematic outline of changes resulting from the lowering of cut-off concentrations of cardiac troponin (cTn) levels in patients
presenting with chest pain to the emergency department.
Originally, cut-off concentration was set according to the definition of acute myocardial infarction by the World Health Organization (WHO).
Universal definition of acute myocardial infarction includes an increase of cTn levels above the 99% percentile of a healthy reference
population at a coefficient of variation -10% (17). While cut-off-levels of conventional cTn assays could not achieve the limit at the 99%
percentile of the reference population due to high variation of results at low cTn concentrations, new, high-sensitivity cTn assays are able
to measure circulating cTn levels in healthy persons at high precision. Lowering of cut-off-points increase sensitivity and the number of
chest pain patients with increased cTn at the cost of specificity. Increased cTn levels are found in almost all patients with acute myocardial
even at the time of presentation at the emergency department (14, 32, 33, 55).
affected patients and the number of resources needed to
exclude cardiac dysfunction. Our own experience showed
that emergency physicians can handle these challenges
without difficulties: the admission rate has not changed
after implementation of the new assay technology (14).
3. Levels of cTn as measured with the new, high-sensitivity
assays are associated with elevated cardiovascular risk in
apparently healthy, middle aged men (30). Few study sub-
jects in this cohort display cTn levels above the recom-
mended new cutpoint for the diagnosis of acute MI (30).
Moreover, even small increases of cTnI levels in patients
presenting with acute chest pain to the ED are indicative
for adverse short- and long-term prognosis (35, 37). Also
of interest, chest pain patients with small increases of cTn
levels, which have been not identified using former assay
generations, may also benefit from early coronary inter-
vention (36).
Circulating cTn are associated with the extent of coronary
artherosclerosis meaning higher plaque burden in subjects
with higher cTn levels (41). Higher cTn levels are associated
with increased overall mortality in affected patients with sta-
ble coronary artery disease (42). Of note, increased cTn con-
centrations in the latter cohort of apparently healthy men
were associated with an increased incidence of cardiovas-
cular death and heart failure but not with an increased rate
of acute MI (42). It is currently unknown whether preventive
actions may beneficially influence this minor, but increased
risk of adverse events.
Summing up, methodological aspects of current cTn
assays have been considerably improved and cTn levels can
be measured even in healthy people. We need to reassess the
currently held belief that cTn is released only from irrevers-
ibly injured myocardial cells and indicated acute MI (13).
Nevertheless, even small increases of cTn levels in patients
with coronary artery disease or heart failure indicate
increased risk of adverse outcome and may be due to various
conditions. The difficulty for the emergency physician is in
deciding how to use this high quality and previously unob-
tainable information (1). It may not be clear whether the new
high-sensitivity cTnI and cTnT methods will lead to more
clarity or confusion in routine clinical practice (28). It is
currently discussed that the time-dependent rise and fall (del-
ta-change) of cTn levels within a few hours of observation
may be supportive for the emergency physician to diagnose
of acute MI.
Time-dependent changes of troponin levels in acute
myocardial infarction
Increased analytical cTn assay sensitivity is associated with
an elevated rate of patients with increased cTn levels pre-
senting to the ED additionally detecting pathological pro-
cesses of the heart other than acute ischemia and/or acute
MI (14, 33). Formally, a time-dependent rising and falling
pattern of cTn levels is included in the definition of acute
MI (17). Due to analytical variability, a 20% time-dependent
change of cTn levels has been suggested to be clinically
meaningful (43). Giannitsis et al. analyzed chest pain patients
with negative cTnT levels at initial presentation and con-
firmed NSTEMI using the 4th generation cTnT assay for
adjudicated diagnosis of acute MI. They found that patients
Christ et al.: Acute chest pain in the emergency department 1959
Article in press - uncorrected proof
with acute MI display a )100% and )200% change of
hs-cTnT levels within 3 and 6 h after initial presentation.
Using those time-dependent delta-change criterium for the
diagnosis of acute MI a 100% positive predictive value is
obtained (44). It is interesting that in most studies examining
the variability of hs-cTnT and hs-cTnI levels in healthy study
subjects, an overall variability )50% has been shown within
a few hours of observation (45–48). These findings confirm
the suggestion that a time-dependent change of hs-cTnI or
hs-cTnT levels )50% may be useful as a important diag-
nostic criterium for the diagnosis of acute MI in the ED.
Aldous et al. examined the introduction of the suggested
time-dependent delta-change criterium for the diagnosis of
acute MI in the ED (49): Introduction of the diagnostic cri-
terium that a time-dependent increase (or fall) of hs-cTn
)50% is necessary to diagnose acute MI increase specificity
)95% at the cost of sensitivity (hs-cTnT: 61.8%; hs-cTnI:
68.2%). These findings support the notion that diagnostic
reasoning in emergency medicine cannot be reduced to pure
mathematical calculations of biomarker concentrations (49,
50). Diagnostic reasoning and deduced therapeutic manage-
ment strategies can only be made correctly, when all avail-
able information about the patient is used. This includes
intuitive and analytical approaches (51) and should consider
prevailing discomfort of the patient, clinical signs and symp-
toms at examination, results of 12-lead electrocardiogram,
and levels and dynamics of cTn levels to calculate post-test
probabilities (50). Moreover, the task of the emergency phy-
sician is not limited to rule in or rule out acute MI in the
ED, but to find the correct triage decision. Emergency phy-
sicians have to identify patients at increased risk for adverse
outcome, who may benefit from hospitalization and/or tai-
lored treatment strategies.
Clinical decision-making in chest pain patients
The recently released document on the ‘‘universal definition
of MI’’ has strengthened the role of cTn increases as an
important criterion for the diagnosis of MI (17). Subsequent-
ly, the emphasis on biomarkers, such as cTn in clinical deci-
sion-making of chest pain patients in ED has increased (15).
However, overreliance on cTn measurements and failure to
consider clinical presentation and ECG findings can lead to
over- and underdiagnosis of MI, each of which carries its
own set of hazards (50, 52).
Cardiac troponins are useful not only because they come
close to fulfilling many of the criteria for an ideal biomarker,
but also because they convey prognostic information and can
help frame therapeutic decisions regarding patients with
acute coronary syndrome. Elevated cTn levels in acute
NSTE-ACS indicates adverse prognosis and coronary inter-
vention appears prudent (3, 4, 36). Note that the introduction
of risk stratification tools using clinical information as the
GRACE risk model may help to identify patients with
increased cTn levels, who benefit from revascularization
(53). Thus, increases of cTn levels combined with clinical
information indicate the need for a specific treatment strat-
egy, which has been shown to be associated with a significant
reduction of death or recurrent MI during follow-up (54). A
recently published study indicates that chest pain patients,
who are newly identified using sensitive cTn assay technol-
ogy, are at increased risk and may benefit from early revas-
cularization (36). However, because these highly precise and
sensitive laboratory assays have not been formally tested
with currently used algorithms (Figure 1), clinical decision-
making for patients presenting with chest pain to the ED
using high-sensitivity cTn assay may change.
Reichlin et al. report results of a multicenter study recruit-
ing 718 consecutive patients who presented with symptoms
suggesting acute coronary syndrome in the ED (33). Using
the 4th generation cTnT assay and all clinical information
obtained during the hospital stay for adjudicated final diag-
nosis of acute MI, 17% of patients of the cohort had acute
MI. Highly sensitive cTnT and cTnI assays at presentation
displayed a significant higher diagnostic accuracy as meas-
ured by the area under receiver-operating-characteristics
curve (AUC) than the standard assay wstandard test: 0.90 vs.
sensitive assays: 0.92–0.98; (33)x. Sensitivity of high-preci-
sion methods to detect acute MI at presentation ranged from
85%–95% compared to 72% using the conventional cTn
assay. However, specificity significantly decreased with the
new method compared to the conventional assay (80% vs.
97%). Comparable results were reported in a prospective
multicenter study of patients with chest pain and even small
increases of sensitive cTnI levels were associated with
increased risk of adverse events within 30 days of follow-up
(32). Several studies confirm the results that high sensitive
cTn assays identify patients with acute MI earlier than less
sensitive assays (11, 44, 55). Introduction of the new method
in routine practice will increase the number of positive test
results without changing the number of tests (55, 56), while
the number of cardiologist consultations increased possibly
due to the challenge in patients with consistently low-posi-
tive results without dynamic changes during follow-up (31).
Recently, we examined the impact of introducing a sen-
sitive cTn test into routine clinical practice (14), 137 con-
secutive patients presenting with acute chest pain were
examined using the 4th generation cTnT assay and the new,
high-sensitivity cTnT assay for the definition of acute MI.
Sensitivity to detect a patient presenting with acute MI at
presentation was significantly lower with the conventional
hs-cTnT compared to the sensitive cTn assay (57% vs.
94.3%). Negative predictive value was higher for hs-cTnT
(97.3%) compared to cTnT (78.6%). Using current cTnT
assays, 7% of chest pain patients presenting to the ED dis-
play cTnT positive, non-vascular cardiac chest pain and the
proportion of patients presenting with chest pain and abnor-
mal hs-cTnT concentrations nearly tripled using the new
assay. The number of patients with unstable angina or cardiac
non-vascular chest pain without cTn elevation significantly
decreased. Patients with acute MI display a significant rise
or fall of hs-cTnT levels within a few hours, while
time-dependent dynamics of hs-cTnT changes were modest
in patients with non-vascular cardiac chest pain. Even mod-
est increases of cTn in this population indicate increased risk
of death or recurrent MI within 6 months of follow-up, while
risk was low in patients with hs-cTnT levels -14 ng/L. It
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was interesting that the risk for an event was highest in chest
pain patients with dynamic changes of hs-cTnT levels )30%
(Figure 3).
Elevated cTn levels in patients with sepsis, hypertensive
emergency, pulmonary embolism, hypotension, renal failure,
or any of several other conditions indicates that myocardial
damage or even non-thrombotic MI has occurred, producing
leakage of cTn. In this situation, the underlying reason of
the disease has to be treated and increased levels of sensitive
cTn possibly indicate worse prognosis but will not change
the management of affected patients (13). Thus, small
increases of cTn levels in patients presenting with chest pain
have to be judged with prudence and adjudication of dis-
position decision should include general risk assessment
(50).
In conclusion, introduction of high-sensitivity cTn assays
increases the sensitivity to identify patients with acute MI
even at the time of initial presentation in the ED at the cost
of specificity. Several studies indicate that even small
increases of cTn levels are clinically relevant. Some inves-
tigators propose that the specificity of high sensitive assays
to diagnose acute MI may be improved using a defined time-
dependent delta-change criterium wsee above, (44, 57)x.
However, introduction of those criteria may again decrease
sensitivity to diagnose acute MI and should therefore be used
only within the clinical context. Correct interpretation of the
low-positive cTn results is important for development of
algorithms that help to triage affected patients without over-
or underuse of consultation or invasive treatment.
How to use high-sensitive cTn assays in clinical
practice?
New, high-sensitivity cTn assays display several advantages
for patients presenting with acute chest pain to the ED, such
as potential for earlier detection of acute MI and greater sen-
sitivity in identifying acute myocardial injury. However,
interpretation of results in a distinct patient with acute chest
pain has to be readjusted and a significant rise and/or fall of
cTn levels during serial testing should be included to diag-
nose acute MI (50). Even with conventional cTn assays,
patients can have detectable cTn levels because of etiologies
other than vascular occlusion and the use of high-sensitive
cTnI or cTnT doubles such ‘‘false-positive’’ findings (14).
In the past, lessons interpreting results obtained with new
methods in the diagnosis of acute MI and resulting need for
coronary intervention have been learned after the introduc-
tion of cTn assays in the end of the 1990s (58) and after the
updated definition of acute MI 2000 (59) followed by
improved assay methodology during recent years wFigure 3;
(16)x.
What are the key points for the work with high-sensitive
cTn assays in the ED?
First of all, the ED physician should keep in mind that an
increased high-sensitivity cTn level does not equal the diag-
nosis of acute MI and therefore should not necessarily lead
to ACS-directed care. However, increased cTn levels indicate
adverse outcome, while prognosis of patients with cTn levels
below the 99th percentile cutpoint is favorable. Of note, cTn
levels below the cut-off-point even during follow-up do not
exclude the necessity of further work-up of troponin-negative
ACS, although cTn levels below the cut-off-point indicate
beneficial prognosis (14).
Second, ED diagnosis of acute MI consists of the correct
interpretation of the triad of I) typical clinical presentation,
II) interpretation of the 12-lead ECG, and III) increased lev-
els of cTn with a rising and falling pattern of cTn during
follow-up.
Dynamic changes of cTn during follow-up do not indicate
acute MI due to coronary obstruction, but rather an acute
myocardial injury (e.g., MI, sepsis, hypertensive emergency,
pulmonary embolism, acute heart failure or tachyarrhyth-
mia). Clinical probability of ACS is essential to make the
correct triage decision (49, 50, 60). Recently, a formal eval-
uation of pretest probability has been performed using TIMI
risk score and further patient disposition was done after
determination of post-test probability using a cardiac multi-
marker assay. Using this approach, safe patient discharge
could be reduced to 2 h (12). Additional use of non-invasive
imaging or stress testing may support the request for a cor-
rect decision in the ED.
Third, new high-sensitivity cTn assays are able to detect
levels of cTn that would register as zero with conventional
assays (14, 32, 33, 55). Thus, acute myocardial damage will
be detected earlier than with the use of former assays. Spe-
cifically, patients presenting within 3 h after onset of chest
pain may have raised cTn levels (33). Those data and our
own experience indicate that serial cTn testing may be short-
ened to 2 or 3 h after initial presentation of chest pain
patients to the emergency department (11). However, pro-
spective data of how to use new cTn measurement are cur-
rently rare and a follow-up of patients at risk with follow-up
of 12-lead ECG and cTn determination should be guaranteed
until further data are available (9–12 h after onset of symp-
toms or 6–9 h after presentation to the ED).
Fourth, we need to reassess the current hypothesis that cTn
is released only from irreversibly injured myocardial cells.
Even apparently healthy subjects with reentrant tachycardia
or after strenuous exercise will display increased levels of
high-sensitive cTn with a rise and falling pattern during fol-
low-up. However, absolute concentrations of cTn levels are
usually low. Correct disposition decision depends on the cor-
rect interpretation of pretest probabilities as discussed above
(8, 60, 61). The use of a defined height of dynamic changes
of cTn levels during follow-up as suggested (44, 57) may
not adequately address this challenge, since specificity may
decrease and even small increases of cTn may indicate
microinfarction coexistent with plaque rupture and even tro-
ponin-negativity may harbor the risk for adverse events (28,
49). Possibly, clinical decision aids will help to overcome
these problems (5). However, some of these aids have been
tested in the pre-troponin era questioning their validity with
the use of new sensitive assays and a recent metanalysis
suggests that clinical decision aids may be helpful but will
not substitute the experience of an emergency physician (62,
63). Furthermore, technical advances of revascularization
have been considerably improved in the meantime changing
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Figure 3 Kaplan-Meier analysis of patients presenting with acute chest pain to the emergency department.
The event rate (combined endpoint: death or recurrent myocardial infarction during 7 months of follow-up) was low in patients with
hs-cTnT levels -14 ng/L, while patients with cTnT levels G40 ng/L were at an increased risk for the combined endpoint. Patients with
hs-cTnT levels G14 ng/L and cTnT levels -40 ng/L had an intermediate risk (A). Risk for the combined endpoint was highest in patients
with a rise or fall of hs-cTnT levels )30% within the first 24 h after presentation (B). Vertical lines indicate censoring of data. Modified
from (14).
the management of affected patients compared to treatment
in the past. For decision- and disposition-making in the ED,
we use the algorithm recently suggested, which includes
individual risk assessment by an experienced emergency
physician wFigure 1;(4)x. Collinson asked whether troponins
are confusing, and answered ‘‘not really, unless you stop
thinking clinically’’ (64), which is true more than ever.
Conclusions
New, high-sensitivity cTn assays will enable physicians to
both confirm and exclude MI sooner than is now possible in
patients presenting with acute chest pain to the ED, but serial
cTn testing remains necessary. With the increased sensitivity
of new cTn assays, the proportion of patients with cTn pos-
itive, non-vascular cardiac chest pain may increase substan-
tially. Therefore, electrocardiographic and clinical probability
of acute coronary syndrome become more, not less impor-
tant, in order to come to the correct triage decision in the
ED (50). cTnI or cTnT levels below the 99th percentile
cutpoint and lack of a rise and falling pattern of cTnI/cTnT
levels during follow-up indicates beneficial prognosis, but do
not exclude the diagnosis of relevant coronary artery disease.
Failure to consider clinical presentation and ECG findings
appropriately, and overreliance on cTn measurement may
lead to both, over- and underdiagnosis of acute coronary syn-
drome including MI or unstable angina, each of which car-
ries its own hazards (52).
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